Clinical trials: Treatment-Refractory Schizophrenia
Treatment-refractory Schizophrenia
Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study
The purpose of the study is to determine whether addition of electroconvulsive therapy to antipsychotic treatment improves the mental health of patients with treatment-resistant schizophrenia.
- Trial name
- NCT01948999
- Testing
- ECT, Anesthesia
- Volunteers
- 3 people
- Sponsor
- University of Aarhus
Hallucinations, Schizophrenia
Multimodal MRI-guided rTMS to Treat Refractory Hallucinations
The efficacy of neuro-navigated rTMS for patients with schizophrenia suffering from drug-resistant multisensory hallucinations will be tested by the implementation of a double-blind randomized controlled trial (RCT) This study…
- Conditions
- Hallucinations, Schizophrenia, Perceptual Disorders
- Trial name
- MULTIMODHAL (NCT01373866)
- Testing
- MagPro X100 repetitive Transcranial Magnetic Stimulation
- Where
- 2 sites in France
- Volunteers
- 85 people
- Sponsor
- University Hospital, Lille
Treatment-resistant Schizophrenia
The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset
Previous long-term follow-up studies on patients with first-episode schizophrenia have shown that up to 30% of patients who have never received antipsychotic medication treatment do not experience symptom relief or have poor…
- Trial name
- NCT06128408
- Testing
- risperidone, olanzapine, aripiprazole
- Volunteers
- 300 people
- Sponsor
- Peking University
Auditory Hallucination, Verbal, Treatment-resistant Schizophrenia
Avatar Therapy in Comparison to Cognitive Behavioral Therapy for Treatment-resistant Schizophrenia
Schizophrenia is associated with long-lasting health, social and financial burden for patients, families, caregivers and society. Unfortunately, 25-30% of schizophrenia patients respond poorly to antipsychotic medication.
- Trial name
- NCT03585127
- Testing
- Cognitive Behavioral Therapy, Avatar Therapy
- Where
- Canada
- Volunteers
- 74 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Treatment Resistant Schizophrenia Based on the DTMS
Exploration of the Deep Transcranial Magnetic Stimulation for Treatment Resistant Schizophrenia
Negative symptoms and cognitive dysfunction are of importance for the prognosis of the patients of schizophrenia. Based on the hypothesis that deep transcranial magnetic stimulation(dTMS) on prefrontal cortex #PFC# could…
- Trial name
- NCT05167942
- Testing
- deep transcranial magnetic stimulation with H1 coil, High frequency deep transcranial magnetic stimulation with H1 coil, iTBS deep transcranial magnetic stimulation with H1 coil
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Schizoaffective
Treatment of Refractory Schizophrenia With Riluzole
The proposed study would evaluate the benefits of riluzole add-on treatment to patients with schizophrenia who are already receiving medications, but still experience symptoms.
- Trial name
- NCT00375050
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Yale University
Schizophrenia Disorders, Schizo Affective Disorder
SEEG-Guided DBS for Schizophrenia
This is a prospective, randomized, interventional study designed to evaluate the efficacy and safety of SEEG-guided deep brain stimulation (DBS) for symptom improvement in patients with treatment-resistant schizophrenia.
- Trial name
- NCT07671261
- Testing
- SEEG implantation, Deep brain stimulation
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital
Treatment Resistant Schizophrenia, Schizophrenia
Magnetic Seizure Therapy for Schizophrenia - Trial
This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).
- Conditions
- Treatment Resistant Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- MAST (NCT06672588)
- Testing
- Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT)
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia
This is a randomized, placebo-controlled study to assess the efficacy and safety of ATX augmentation of CLZ as a treatment for the cognitive symptoms of schizophrenia.
- Trial name
- NCT00216281
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Indiana University
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia
This a randomized double-blind placebo controlled trial which aims to determine the beneficial effects of minocycline augmentation to clozapine in partial responders to Treatment Resistant Schizophrenia (TRS).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT02533232
- Testing
- Minocycline
- Where
- 4 sites in Pakistan
- Volunteers
- 60 people
- Sponsor
- Pakistan Institute of Living and Learning
Schizophrenia
A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia. This study is not recruiting in the United States.
- Trial name
- NCT00250575
- Testing
- Clozapine
- Where
- 8 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Novartis
Treatment Resistant Schizophrenia
Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation
Approximately 1% of the general population will be affected by schizophrenia over the course of their lives, with life expectancy being reduced by 20 years on average and quality of life being severely diminished in affected…
- Trial name
- HALLUSTIM (NCT06361160)
- Testing
- Active Transcranial Magnetic Stimulation (TMS)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia
Brain Activation Patterns in Schizophrenia After Computerized Cognitive Skills Training
This project is a novel exploratory research project to investigate changes in activation patterns of the dorsolateral prefrontal cortex (DLPFC) in inpatients with schizophrenia who received a 12-week computerized cognitive…
- Trial name
- fMRI (NCT00431223)
- Testing
- Cognitive remediation therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Manhattan Psychiatric Center
Schizophrenia, Treatment-resistant Schizophrenia
Neural Biomarkers of Clozapine Response
Clozapine has consistently shown to be a superior drug for psychosis in patients who do not respond to other treatments, but its mechanism of action remains unknown.
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT03076346
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pittsburgh
Symptom, Cognitive, Schizophrenia
Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate
Although antipsychotic is effective for schizophrenia, however, still certain proportion of patients were not responsive to treatment. Treatment resistant schizophrenia (TRS) is accompanied by function decline and heavy burden.
- Conditions
- Symptom, Cognitive, Schizophrenia, Schizo Affective Disorder
- Trial name
- NCT06340789
- Testing
- Sodium Benzoate 2gram/day
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- National Cheng-Kung University Hospital
Schizophrenia
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia. Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple…
- Trial name
- NCT01244828
- Testing
- Asenapine
- Volunteers
- 157 people
- Sponsor
- Organon and Co
Schizophrenia
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia
The purpose of the study is to investigate whether blockade of the histamine H2 receptors in the brain will have any beneficial effect on the symptoms of subjects with schizophrenia.
- Trial name
- NCT00565175
- Testing
- famotidine
- Where
- 5 sites in Finland
- Volunteers
- 30 people
- Sponsor
- Jesper Ekelund
Treatment-resistant Schizophrenia
Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia
This pilot study aims to investigate the use of MRI-guided low-intensity focused ultrasound (LIFU) to modulate neuronal activity within the thalamus in human subjects with treatment-resistant schizophrenia.
- Trial name
- NCT05259306
- Testing
- Insightec Exablate Neuro MR-guided focused ultrasound transducer
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Schizophrenia, Treatment Refractory
GlyT-1 Inhibitor Treatment for Refractory Schizophrenia
The etiology of schizophrenia remains unclear In recent one decade, hypofunction of N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.
- Trial name
- NCT01251055
- Testing
- GlyT-1 inhibitor-1
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- China Medical University Hospital
Treatment-resistant Schizophrenia
Efficacy and Safety of Temporal Interference Stimulation in Treatment-Resistant Schizophrenia: An Exploratory Study.
This exploratory study aims to evaluate the preliminary efficacy and safety of temporal interference (TI) stimulation in patients with treatment-resistant schizophrenia (TRS).
- Trial name
- NCT07773831
- Testing
- Temporal Interference Stimulation
- Volunteers
- 20 people
- Sponsor
- Zhimin Wang